Segall Bryant & Hamill’s Krystal Biotech KRYS Stock Holding History

Segall Bryant & Hamill’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$24.2M	Sell	65,211 -14,286	-18%	-$4.27M	0.29%	109
2026 Q1	$20.5M	Sell	79,497 -3,749	-5%	-$998K	0.29%	114
2025 Q4	$20.5M	Sell	83,246 -2,017	-2%	-$425K	0.28%	124
2025 Q3	$15.1M	Sell	85,263 -63,351	-43%	-$9.48M	0.2%	172
2025 Q2	$20.4M	Buy	148,614 +3,277	+2%	+$481K	0.29%	116
2025 Q1	$26.2M	Sell	145,337 -3,972	-3%	-$668K	0.4%	75
2024 Q4	$23.4M	Sell	149,309 -7,835	-5%	-$1.39M	0.32%	97
2024 Q3	$28.6M	Buy	157,144 +122,407	+352%	+$23.6M	0.39%	79
2024 Q2	$6.38M	Buy	+34,737	New	+$5.83M	0.11%	243

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Segall Bryant & Hamill's KRYS Position: Q2 2026 in Review

Segall Bryant & Hamill reduced its Krystal Biotech (KRYS) stake by 18% in Q2 2026, selling an estimated $4.27M and leaving 65,211 shares worth $24.2M. The position accounts for 0.29% of the portfolio, ranked #109.

Segall Bryant & Hamill first reported a position in KRYS in Q2 2024 and has held it in 9 quarters since. The position peaked at $28.6M in Q3 2024. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

Segall Bryant & Hamill held 65,211 shares of Krystal Biotech worth $24.2M as of Q2 2026.
Segall Bryant & Hamill sold 14,286 Krystal Biotech shares in Q2 2026, an estimated $4.27M.
Krystal Biotech made up 0.29% of Segall Bryant & Hamill's portfolio in Q2 2026, its #109 holding.
Segall Bryant & Hamill first reported a position in Krystal Biotech in Q2 2024 and has held it in 9 quarters since.
Segall Bryant & Hamill's Krystal Biotech position peaked at $28.6M in Q3 2024.
424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Segall Bryant & Hamill's 13F filing for Q2 2026, filed 12 Aug 2026.